Monday, September 21, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Sep 18, 2026
Inside the growing world of biopharma prediction markets
background ▾
- •Prediction markets in biopharma create insider trading risk because employees and researchers with access to confidential trial or regulatory data could exploit prediction markets for financial gain.
- •The SEC and regulators are likely to increase enforcement focus on biopharma prediction markets, mirroring their approach to other information-sensitive sectors.
- •Companies should immediately establish compliance frameworks, trading restrictions, and employee awareness programs to manage insider information risks in prediction markets.
Pillsbury Winthrop Shaw Pittman
→ Read original articlePolicy•Fierce Biotech•Sep 18, 2026
FDA clears Aptitude’s latest Metrix molecular dx to test for COVID
background ▾
- •510(k) clearance removes regulatory uncertainty and enables full commercial positioning post-EUA termination, positioning Aptitude for sustained COVID dx revenue in a non-emergency market
- •Transition strategy (allowing existing EUA stock to remain in use) mitigates customer disruption risk during the shift from emergency to standard regulatory frameworks
- •Pipeline expansion into RSV, strep, and STI diagnostics signals platform diversification beyond COVID, reducing single-indication dependency
Aptitude Medical SystemsMetrix COVID diagnosticMetrix COVID/Flu
→ Read original articlePolicy•STAT News•Sep 21, 2026
Opinion: STAT+: The NIH budget should be $100 billion per year
background ▾
- •Daraxonrasib approval demonstrates the first successful KRAS inhibitor for pancreatic cancer, achieving ~50% survival improvement in trials
Revolution Medicinesdaraxonrasib
→ Read original articlePolicy•STAT News•Sep 21, 2026
Why is trust in science important?
background ▾
- •This is organizational news about a media outlet's editorial strategy, not substantive pharma industry or regulatory news
Policy•STAT News•Sep 21, 2026
Skeptical about modern medicine? I know the feeling — and want to listen
background ▾
- •Trust in science is driven more by emotional factors (fear, frustration, desperation) than by scientific literacy or deliberate misinformation—a framing that has implications for how the industry communicates value and addresses patient concerns
SSRIsNAC (N-acetylcysteine)
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 21, 2026
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
background ▾
- •Telix gains direct competition to Novartis' Lutathera and Pluvicto through ITM-11 and TLX591, with a two-front RLT strategy backed by vertically integrated lutetium-177 supply
- •ITM-11 FDA resubmission is a closing condition; approval by end-2025 triggers $100M milestone, with potential for $250M total regulatory milestones, creating binary near-term catalysts
- •Combined entity expected to generate $1.3B in 2025 revenue; watch for ITM-11 manufacturing remediation progress and FDA pre-submission meeting outcomes
Telix PharmaceuticalsITM Isotope Technologies MunichNovartisITM-11TLX591Lutathera
→ Read original articleMarket Access•Fierce Biotech•Sep 21, 2026
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
background ▾
- •TRex Bio has ~$91M in cash, 60 employees, and a validated Treg modulation platform with Lilly collaboration and option participation, positioning it as a better-capitalized IPO candidate than Retension
- •Retension's RTN-001 represents a clinically differentiated next-gen PDE-5 inhibitor with improved bioavailability targeting an underserved hypertension segment, but the company is under-resourced with only $13.5M cash and 12 employees
TRex BioRetension PharmaceuticalsEli LillyTRB-061TRB-071RTN-001
→ Read original articleMarket Access•Fierce Biotech•Sep 18, 2026
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
background ▾
- •Ingrid Zhang brings 15 years of Big Pharma commercial expertise (Novartis, AstraZeneca, Pfizer) to maximize Carvykti's market penetration as CAR-T competition intensifies
- •Carvykti achieved $657M in Q2 2026 sales with 32% YoY U.S. growth and 128% ex-U.S. expansion across 19 global markets, demonstrating strong commercial momentum
- •Watch for Carvykti's market performance against emerging CAR-T competitors and Legend's ability to sustain international expansion under new commercial leadership
Legend BiotechNovartisJohnson & JohnsonCarvykti
→ Read original articleMarket Access•STAT News•Sep 19, 2026
Jehovah’s Witnesses allow blood-derived products but keep ban on whole-blood transfusions
background ▾
- •Jehovah's Witnesses now permit use of individual blood components (plasma, platelets, RBCs, WBCs) derived from donated blood, a significant expansion of prior restrictions that could improve clinical outcomes in trauma and surgical care for affected patients.
- •The policy change allows both receipt and donation of blood-derived products on individual conscience basis, potentially expanding the donor pool and availability of blood products for medical use.
Market Access•Endpoints News•Sep 18, 2026
Legend names new CEO as Carvykti competition grows; Vertex makes a flurry of moves
background ▾
- •Legend Biotech's CEO transition to a Novartis veteran signals potential strategic repositioning as Carvykti faces growing competitive pressure in CAR-T market
- •Vertex's undisclosed 'flurry of moves' suggests active competitive maneuvering in cell therapy space, warranting close monitoring of announcements
Legend BiotechNovartisVertexCarvykti
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 21, 2026
Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy
background ▾
- •Beacon's laru-zova achieved clinically meaningful visual acuity improvements in XLRP patients in a pivotal trial, meeting primary endpoint and positioning the company for near-term FDA filing
- •Beacon succeeded where Biogen and J&J/MeiraGTx failed by using a functionally relevant primary endpoint (low-light reading acuity) and employing codon optimization to stabilize the full-length RPGR gene
- •Regulatory decision point approaching: rolling BLA submission expected before end of 2024; watch for FDA feedback, potential partnership announcements, and Phase 3 data maturation from competing programs
Beacon TherapeuticsBiogenJohnson & Johnsonlaruparetigene zovaparvovec
→ Read original articleClinical Trials•Fierce Biotech•Sep 21, 2026
Cue chalks up phase 2 hives win for Xolair challenger
background ▾
- •CUE-221 achieved statistically significant superiority over placebo on primary endpoint (HSS7 at Week 12: 43-54% vs 11%) and demonstrated numerical superiority over Xolair comparator (43-54% vs 41%), with separation widening durably through Week 28.
- •The mechanism differentiation claim—IgE production downregulation beyond Xolair's IgE neutralization—is supported by deeper and more durable responses, positioning CUE-221 as a potential best-in-class asset in a large CSU market dominated by omalizumab.
- •Watch for phase 2b/3 trial initiation timeline and enrollment pace; competitive pressure from Xolair generics and emerging CSU therapies (including other anti-IgE approaches); and food allergy phase 2 data, which could expand the addressable patient population.
Cue BiopharmaAscendant Health SciencesNovartisCUE-221Xolairomalizumab
→ Read original articleClinical Trials•Fierce Biotech•Sep 18, 2026
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
background ▾
- •ART27.13 demonstrated ~20% weight loss in obese mice comparable to semaglutide monotherapy, and ~40% weight loss when combined with semaglutide, with 80% of weight loss attributable to fat
- •Positive phase 2 interim data in cancer cachexia showed 6% body weight gain at highest dose over 12 weeks versus 5% loss in placebo, supporting potential dual indication strategy
- •Company actively pursuing partnership discussions; monitor for clinical advancement in obesity indication and any partnerships that could accelerate development or expand market access
Artelo BiosciencesAstraZenecaNeomed InstituteART27.13AZD1940semaglutide
→ Read original articleClinical Trials•Endpoints News•Sep 19, 2026
Another Novartis failure; Novo drops the ‘Nordisk’; and more
background ▾
- •Novartis reported a clinical trial failure, representing a pipeline setback for a major pharmaceutical company
- •Novo Nordisk is undergoing a significant corporate change (rebranding or strategic shift), indicating potential strategic repositioning
NovartisNovo Nordisk
→ Read original articleClinical Trials•Fierce Biotech•Sep 18, 2026
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
background ▾
- •K-554 represents a potential first-in-class non-incretin peptide approach to obesity, offering a mechanistically distinct alternative to GLP-1 drugs and targeting a different biological pathway for food intake regulation
- •Novo is actively broadening its obesity pipeline through external partnerships (three Kallyope programs plus the Orbis macrocycle deal within 24 hours), signaling aggressive portfolio building to compete with Lilly
- •K-554 Phase 1 readout in H2 2026 will be a key inflection point to monitor for clinical validation of the non-incretin obesity approach and competitive differentiation
Novo NordiskKallyopeEli LillyK-554semaglutideziltivekimab
→ Read original article